Imatinib Mesylate Tablet, Film Coated
Product Images NDC 0378-2245

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 0378-2245). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib Structural Formula (Image 01)

Chemical structure of imatinib mesylate, the active ingredient in Imatinib Mesylate tablets. The structure shows aromatic rings, nitrogen-containing heterocycles, and the mesylate group typical of this molecular compound.*

FDA Label Image

Imatinib Tablets 100 mg Bottle Label (Image 02)

Imatinib Mesylate 100 mg film-coated tablets label from Mylan Pharmaceuticals Inc. The label states each tablet contains imatinib mesylate equivalent to 100 mg imatinib. It includes dispensing and storage instructions, emphasizing child-resistant containers and moisture protection. The package contains 90 tablets and is marked Rx only. Made in Puerto Rico with a NDC of 0378-2245-77.*

FDA Label Image

Imatinib Tablets 400 mg Bottle Label (Image 03)

Imatinib Mesylate 400 mg film-coated tablets bottle label by Mylan Pharmaceuticals Inc. The label states the active ingredient strength as 400 mg imatinib per tablet and includes the NDC number 0378-2246-93. It mentions storage instructions, dispensing conditions, and that the package contains 30 tablets for prescription use only.*

FDA Label Image

Figure 1: Progression Free Survival (itt Principle) (Image 04)

A survival curve graph comparing the percentage of patients without progression over months since randomization between two treatment arms: Imatinib and IFN+Ara-C. The graph includes patient counts with progression and censored data, hazard ratio with 95% confidence interval, and significance (P < 0.0001). Imatinib shows a higher percentage of progression-free patients over time than IFN+Ara-C.*

FDA Label Image

Figure 2: Time To Progression To Ap Or Bc (itt Principle) (Image 05)

A Kaplan-Meier plot showing the percentage of patients without progression to AP/BC over 72 months since randomization. The graph compares two groups: Imatinib arm (solid line) and IFN+Ara-C arm (dashed line). Patient numbers at risk, hazard ratio with confidence interval, and log-rank test p-value are included in the figure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.